Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia 2Urinary Bladder Neoplasms 1Recurrence 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

Cytarabine 561Azacitidine 385venetoclax 311Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 187Busulfan 176Daunorubicin 155Idarubicin 151Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 73Injections 69Stem Cell Transplantation 64Biopsy 57CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × lirilumab × Clear all
NCT02399917 2019-09-24

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Terminated
36 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT01687387 2019-02-08

EFFIKIR

Innate Pharma

Phase 2 Completed
152 enrolled 9 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡